Comparative Pharmacology
Head-to-head clinical analysis: CLOVIQUE versus PLAVIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOVIQUE versus PLAVIX.
CLOVIQUE vs PLAVIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLOVIQUE is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), a pro-inflammatory cytokine. By blocking IL-6 from binding to its receptor, it reduces inflammation and immune responses.
Clopidogrel is a prodrug that is converted to an active metabolite by CYP450 enzymes. The active metabolite selectively inhibits the P2Y12 component of ADP receptors on the platelet surface, which prevents ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
10 mg orally once daily.
75 mg orally once daily, with or without food. For acute coronary syndrome, a loading dose of 300 mg (or 600 mg for PCI) is given followed by 75 mg daily.
None Documented
None Documented
Terminal half-life of 22-30 hours; allows once-daily dosing with steady-state achieved in 5-7 days
Clopidogrel parent: ~6 hours; active thiol metabolite: ~30 minutes; terminal half-life of inactive metabolite(s): ~8 hours. Clinically, platelet inhibition persists for 5–7 days due to irreversible P2Y12 receptor binding.
Renal: 65-75% unchanged; biliary/fecal: 20-25% as metabolites
Renal: ~50% as inactive metabolites; biliary/fecal: ~50% as inactive metabolites.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent